PI3K inhibitors in thrombosis and cardiovascular disease

被引:65
|
作者
Durrant, Tom N. [1 ]
Hers, Ingeborg [2 ]
机构
[1] Univ Oxford, Dept Chem, Oxford OX1 3QZ, England
[2] Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England
来源
CLINICAL AND TRANSLATIONAL MEDICINE | 2020年 / 9卷 / 01期
关键词
Cardiovascular disease; Thrombosis; Platelets; Phosphoinositide; 3-kinase; PI3K; Phosphoinositides; Cellular signalling; II PHOSPHOINOSITIDE 3-KINASE; REGULATES PLATELET ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PI3K-GAMMA INHIBITION; P110-ALPHA ISOFORM; P110-BETA SUBUNIT; CRYSTAL-STRUCTURE; P2Y(12) RECEPTOR; DOSE-ESCALATION; CELL-MIGRATION;
D O I
10.1186/s40169-020-0261-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate important intracellular signalling and vesicle trafficking events via the generation of 3-phosphoinositides. Comprising eight core isoforms across three classes, the PI3K family displays broad expression and function throughout mammalian tissues, and the (patho)physiological roles of these enzymes in the cardiovascular system present the PI3Ks as potential therapeutic targets in settings such as thrombosis, atherosclerosis and heart failure. This review will discuss the PI3K enzymes and their roles in cardiovascular physiology and disease, with a particular focus on platelet function and thrombosis. The current progress and future potential of targeting the PI3K enzymes for therapeutic benefit in cardiovascular disease will be considered, while the challenges of developing drugs against these master cellular regulators will be discussed.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
    Uehara, Mayuko
    McGrath, Martina M.
    Ohori, Shunsuke
    Solhjou, Zhabiz
    Banouni, Naima
    Routray, Sujit
    Evans, Catherine
    DiNitto, Jonathan P.
    Elkhal, Abdallah
    Turka, Laurence A.
    Strom, Terry B.
    Tullius, Stefan G.
    Winkler, David G.
    Azzi, Jamil
    Abdi, Reza
    NATURE COMMUNICATIONS, 2017, 8
  • [22] Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells
    Fateye, Babasola
    Chen, Bin
    OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XX, 2011, 7886
  • [23] Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer
    Wu, Zhengyang
    Bai, Ying
    Jin, Jiaming
    Jiang, Teng
    Shen, Hui
    Ju, Qiurong
    Zhu, Qihua
    Xu, Yungen
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 217
  • [24] The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment
    Qin, Hanjiao
    Liu, Linlin
    Sun, Shu
    Zhang, Dan
    Sheng, Jiyao
    Li, Bingjin
    Yang, Wei
    PEERJ, 2018, 6
  • [25] PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
    Wu, P.
    Hu, Y-Z
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (35) : 4326 - 4341
  • [26] PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present)
    Feng, Yifan
    Cu, Xiaochuan
    Xin, Minhang
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2019, 29 (12) : 925 - 941
  • [27] Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors
    Ma, Chen-Chen
    Zhang, Cheng-Mei
    Tang, Long-Qian
    Liu, Zhao-Peng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 9 - 17
  • [28] Targeting PI3K signaling in cancer: Challenges and advances
    De Santis, Maria Chiara
    Gulluni, Federico
    Campa, Carlo Cosimo
    Martini, Miriam
    Hirsch, Emilio
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (02): : 361 - 366
  • [29] Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors
    Sun, Jiajia
    Feng, Yifan
    Huang, Yuan
    Zhang, San-Qi
    Xin, Minhang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (19)
  • [30] Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
    Ameriks, Michael K.
    Venable, Jennifer D.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 738 - 753